FGFR2 and neoplasm: Taking into account the reported oncogenic role of FGFR2 in luminal A BCa (3–5), we then evaluated the relationship between FGFR2 and immune markers in relation to the ER status, i.e. in luminal A (n=70) versus non-luminal A tumours (n=29).